[EN] CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITES [FR] CYCLOPROPYL DICARBOXAMIDES ET ANALOGUES PRÉSENTANT DES ACTIVITÉS ANTICANCÉREUSES ET ANTIPROLIFÉRATIVES
[EN] PROTEIN KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉINES KINASES
申请人:ORION CORP
公开号:WO2014162039A1
公开(公告)日:2014-10-09
A compound of formula (I), wherein R1 to R5, A, B, Z, Z1 and Z2 are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.
A composition of cysteamine and a compound represented by the formula ##SPC1## Where R is hydrogen, --CHO or ##EQU1## useful for the treatment of an animal infected with a virus.
nucleophilic substitution reaction with amines. The subsequent treatment of the obtained products with aq H2SO4 can lead to either N-denitrosation to obtain 4,6-pyrimidinediamines or to a Fischer-Hepp type rearrangement to obtain 5-nitroso-4,6-pyrimidinediamines. It was found that the outcome of the reaction strongly depends on the structure of the pyrimidines. Activation of the pyrimidine ring by three
N-亚硝基部分可用于将氯嘧啶活化为与胺发生亲核取代反应。所得产物用 aq H2SO4 进行后续处理可导致 N-脱亚硝基得到 4,6-嘧啶二胺,或导致 Fischer-Hepp 型重排以得到 5-亚硝基-4,6-嘧啶二胺。发现反应的结果在很大程度上取决于嘧啶的结构。三个具有正中间体效应的基团激活嘧啶环对于分子内亚硝基迁移至关重要。
CYCLOPROPYL DICARBOXAMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES
申请人:Flynn Daniel L.
公开号:US20120252849A1
公开(公告)日:2012-10-04
The disclosed compounds are useful in the treatment of mammalian cancers and especially human cancers. Compounds, pharmaceutical compositions, and methods of Formula I are disclosed:
or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, stereoisomer, or tautomer thereof.
Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activities
申请人:Flynn Daniel L.
公开号:US08637672B2
公开(公告)日:2014-01-28
The disclosed compounds are useful in the treatment of mammalian cancers and especially human cancers. Compounds, pharmaceutical compositions, and methods of Formula I are disclosed:
or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, stereoisomer, or tautomer thereof.